ArticleJournal of neuroinflammation2018
Genetically enhancing the expression of chemokine domain of CX
Article in Journal of neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 22 citations in OpenAlex.
- Matrix metalloproteinase-9 is associated with CX3CL1 on tau and amyloid biomarker pathways in APOE4 carriers.Neurobiology of disease · 2026Trial
- Targeting microglia-mediated neuroinflammation in Alzheimer's disease: mechanisms and therapeutic approaches.Frontiers in immunology · 2026Review
- Beyond Neuroinflammation: Microglia at the Crossroads of Amyloid, Tau, and Neurodegeneration in Alzheimer's Disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- CX3CL1 Regulation of Gliosis in Neuroinflammatory and Neuroprotective Processes.International journal of molecular sciences · 2025Review
- Global Deficiency of Alzheimer's Disease Risk GeneASN neuro · 2025Article
- Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets.Signal transduction and targeted therapy · 2023Review
- CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer's Disease.International journal of molecular sciences · 2023Review
- Article
- Microglial Activation and Priming in Alzheimer's Disease: State of the Art and Future Perspectives.International journal of molecular sciences · 2023Review
- Age-dependent changes on fractalkine forms and their contribution to neurodegenerative diseases.Frontiers in molecular neuroscience · 2023Review
- Role of Chemokines in the Development and Progression of Alzheimer's Disease.Journal of molecular neuroscience : MN · 2022Review
- Microglia in Alzheimer's Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Interleukin-10 deficiency exacerbates inflammation-induced tau pathology.Journal of neuroinflammation · 2021Article
- Microglia Biomarkers in Alzheimer's Disease.Molecular neurobiology · 2021Review
- Marked Mild Cognitive Deficits in Humanized Mouse Model of Alzheimer's-Type Tau Pathology.Frontiers in behavioral neuroscience · 2021Article
- Microglia in Alzheimer's Disease in the Context of Tau Pathology.Biomolecules · 2020Review
- Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice.Journal of neuroinflammation · 2020Article
- Synaptic Loss in Alzheimer's Disease: Mechanistic Insights Provided by Two-PhotonFrontiers in cellular neuroscience · 2020Review
- Microglial priming of antigen presentation and adaptive stimulation in Alzheimer's disease.Cellular and molecular life sciences : CMLS · 2019Review
- Intersection of pathological tau and microglia at the synapse.Acta neuropathologica communications · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundFractalkine (CX
methodsWe used transgenic mice lacking endogenous Cx
resultsFirst, increased basal tau levels accompanied microglial activation in Cx
conclusionsCollectively, our data suggest that overexpression of only chemokine domain of CX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.